This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vaage, J. Search for Related Content PubMed PubMed Citation Articles by Vaage, J.

Concomitant Immunity and Specific Depression of Immunity by Residual or Reinjected Syngeneic Tumor Tissue¹

Section of Experimental Radiotherapy, The University of Texas M. D. Anderson Hospital and Tumor Institute at Houston, Houston, Texas 77025

Mice given injections of living methylcholanthrene-induced fibrosarcoma cells after the complete surgical removal of a growing, sensitizing tumor implant showed a strong immune resistance to the growth of the injected cells. If the sensitizing tumor was left in situ until 4 days after the challenge injection of tumor cells or if the tumor was killed with irradiation and left to regress, the immune resistance of the host was impaired but not abrogated. The depression was specific, since the presence of a growing, antigenically unrelated tumor did not impair the resistance to the sensitizing fibrosarcoma. Injection of graded doses of killed tumor cells of the fibrosarcoma and of the antigenically unrelated tumor, a mammary carcinoma, showed that, at moderate and low doses, only the injection of fibrosarcoma cells depressed host resistance. Large doses of either tumor depressed host resistance, probably in part because of nonspecific toxic depression.

¹ This work was supported in part by USPHS Grants CA05047, CA6294, CA11430, and CA11138 from the NIH.

² Present address: Department of Radiation Medicine, Massachusetts General Hospital, Boston, Mass. 02114.

Received 4/ 8/71. Accepted 6/25/71.

This article has been cited by other articles:

				H. N. Le, N. C. Lee, K. Tsung, and J. A. Norton Pre-Existing Tumor-Sensitized T Cells Are Essential for Eradication of Established Tumors by IL-12 and Cyclophosphamide Plus IL-12 J. Immunol., December 15, 2001; 167(12): 6765 - 6772. [Abstract] [Full Text] [PDF]

				J. W. Rohrer, A. L. Barsoum, D. L. Dyess, J. A. Tucker, and J. H. Coggin Jr. Human Breast Carcinoma Patients Develop Clonable Oncofetal Antigen-Specific Effector and Regulatory T Lymphocytes J. Immunol., June 1, 1999; 162(11): 6880 - 6892. [Abstract] [Full Text] [PDF]

				R. McBride, D. Watanabe, and L. Schierman Rous sarcomas in chickens: enhanced growth coexisting with concomitant immunity Science, September 9, 1977; 197(4308): 1079 - 1082. [Abstract] [PDF]